According to recent reports, when inhibition of CX3CR1 is targeted early, or CX3CL1 expression levels are increased, administration of exogenous CX3CL1 after ischemia can reverse the neurological damage caused by stroke to some extent (81, 82). This evidence concerns the gene CX3CR1 and ischemia.